Medical Journals

Amyloid Beta-peptide1-42 Alters Tight Junction Protein Distribution and Expression in Brain Microvessel Endothelial Cells.

Authors:
  • Marco Sonia
  • Skaper Stephen D

From: Neurology and GI Centre of Excellence for Drug Discovery, GlaxoSmithKline Research and Development Limited, New Frontiers Science Park, Third Avenue, CM19 5AW Harlow, Essex, United Kingdom.

Neuroscience letters

  • Publish Date: Jul 2006
  • ISSN: 0304-3940
  • Volume: 401
  • Issue: 3
  • Pages: 219-24
  • Medium: Print
  • Language: English
  • Citation (JAMA): Marco Sonia, Skaper Stephen D, et al. Amyloid Beta-peptide1-42 Alters Tight Junction Protein Distribution and Expression in Brain Microvessel Endothelial Cells.. Neurosci. Lett. Jul 2006;401:219-24

Abstract

Alzheimer’s disease is characterised by neuronal loss, numerous intraneuronal deposits of neurofibrillary tangles, senile plaques, and cerebrovascular amyloid deposits. The major component of senile plaques and cerebrovascular deposits is the 39-43 amino acid beta-amyloid peptide (Abeta). The effects of Abeta on cerebral endothelium and thus the blood-brain barrier remain unclear. Utilising endothelial cells isolated from rat cerebral cortex microvessels, we have examined effects of Abeta peptides on tight junction protein behaviour. The transmembrane tight junction proteins occludin, claudin-1 and claudin-5, as well as the cytoplasmic accessory proteins ZO-1 and ZO-2 displayed a continuous distribution at cell boundaries. Endothelial cells exposed to Abeta1-42 (20 microM) for 3 days showed a disrupted plasma membrane pattern of claudin-5 and ZO-2 with relocation to the cytoplasm. These effects were not seen with Abeta25-35 or Abeta1-40[Gln22] (Dutch type). Abeta1-42 treatment altered also protein expression: occludin was lower at 1st day, claudin-1 increased at all times, and ZO-2 increased after 1 day and then decreased. These data suggest that Abeta1-42 effects on tight junction protein complexes may alter blood-brain barrier integrity and contribute to the neuropathological sequelae of Alzheimer’s disease.

Mesh Headings (Keywords): Amyloid beta-Protein, Animals, Cells, Cultured, Cerebral Cortex, Endothelial Cells, Endothelium, Vascular, Fluorescent Antibody Technique, Gene Expression, Membrane Proteins, Peptide Fragments, Rats, Time Factors


Check for Full Text / PubMed Unique Identifier (PMID): 16644119


This abstract is part of PubMed, a service of the U.S. National Library of Medicine. PubMed includes more than 17 million citations from MEDLINE and other life science journals for biomedical articles. See Copyright and Disclaimers.

Linked medical terms appearing on this page are added by Healia to help readers find more information and are not part of the original PubMed document.

The data herein was last updated on July 8th, 2008 and may not reflect the most current and accurate data available from NLM.


Advertisements

About | Privacy Policy | Business Solutions | Advertise | Contact | Add Healia to your site

©2012. Healia / Meredith Corporation  

Use of this site constitutes acceptance of our Terms of Service and Privacy Policy. All content on this Web site, including medical opinion and any other health-related information, is for informational purposes only and should not be used for a specific diagnosis or individual treatment plan for any situation. Use of this site and the information contained herein does not create a doctor-patient relationship. Always seek the direct advice of your doctor in connection with any questions or issues you may have regarding your own health or the health of others.